Omnicell — Third Quarter 2026 Earnings Summary

Financial Performance:

• Total revenues for Q3 2026 were $308 million, a 1% decrease ($3 million) compared to Q3 2025.
• GAAP net income for Q3 2026 was $11 million ($0.24 per diluted share), compared to $5 million ($0.12 per diluted share) in Q3 2025.
• Non-GAAP net income for Q3 2026 was $27 million ($0.58 per diluted share), compared to $24 million ($0.51 per diluted share) in Q3 2025.
• Non-GAAP EBITDA for Q3 2026 was $45 million, compared to $41 million in Q3 2025.
• Cash flows provided by operating activities in Q3 2026 totaled $33 million, compared to $28 million in Q3 2025.
• As of September 30, 2026, cash and cash equivalents were $315 million, total debt was $169 million, and total assets were $2.1 billion.
• The company had $350 million available under its revolving credit facility with no outstanding balance as of September 30, 2026.
• Deferred revenues (current and long-term) totaled $263.6 million as of September 30, 2026 ($199.8 million current, $63.8 million long-term).

Guidance and Future Outlook:

• Omnicell increased full-year 2026 non-GAAP EBITDA guidance to $187 million – $193 million and non-GAAP earnings per share guidance to $2.48 – $2.56.
• Full-year 2026 total revenue guidance was tightened to $1.225 billion – $1.231 billion.
• Full-year 2026 product revenue guidance is $684 million – $687 million; service revenue guidance is $541 million – $544 million.
• Full-year 2026 annual recurring revenue guidance is $660 million – $670 million.
• Full-year 2026 product bookings guidance remains $425 million – $560 million.
• Q4 2026 total revenue guidance is $295 million – $301 million; non-GAAP EBITDA is $30 million – $36 million; non-GAAP EPS is $0.41 – $0.49.
• Management cited strong momentum with the next-generation platform (Titan XT and OmniSphere) and a growing pipeline.

Business Segments and Product Lines:

• Q3 2026 product revenues were $173 million; service revenues were $135 million.
• Nine months 2026 product revenues were $523 million; service revenues were $407 million.
• Customers are validating the value of combining Titan XT with OmniSphere, the cloud-native platform, to improve productivity, efficiency, and workflow reliability.
• The company focuses on solutions designed to improve operational efficiency, optimize medication workflows, and address workforce challenges.

Market and Competitive Landscape:

• Healthcare providers are prioritizing solutions that improve operational efficiency and medication management.
• Omnicell positions itself to capitalize on a significant long-term opportunity in autonomous medication management.
• The company noted continued competition in the medication management automation solutions market and the medication adherence solutions market.

Risks and Challenges:

• Risks include unfavorable economic conditions, delays in purchasing decisions, and variability in forecasting product bookings.
• Potential delays in installations of medication management solutions and complex medication packaging systems.
• Risks related to the incorporation of AI technologies, cybersecurity breaches, and data security.
• Substantial debt levels and covenants in the credit agreement could restrict business operations.
• Dependence on a limited number of suppliers for certain components and raw materials.
• Risks associated with government regulations, legislative changes, and the 340B Program.

Management Commentary and Tone:

• Randall A. Lipps, Chairman, CEO, and Founder, stated the company delivered solid results and continued to execute against strategic priorities.
• Management highlighted disciplined cost management and favorable product and service margins as key drivers.
• Lipps expressed confidence in the next-generation platform's potential to drive productivity and efficiency across the medication-use process.
• The tone was confident, noting that revenue and profitability came in above the high end of the previously provided guidance range.

Other Key Points:

• Omnicell held its sixth annual Illuminate event, a virtual education and best practice sharing event for healthcare leaders.
• The company issued its 2025 Environmental, Social, and Governance (ESG) Report.
• Non-GAAP financial measures exclude share-based compensation, amortization of acquired intangibles, acquisition-related expenses, restructuring costs (Professional Services, Product organization, EnlivenHealth, China), legal and regulatory expenses, management severance costs, executives transition costs, and amortization of debt issuance costs.
• Non-GAAP free cash flow for the nine months ended September 30, 2026, was $114.4 million.
• The company does not provide forward-looking guidance for GAAP net income or GAAP earnings per share.